🇺🇸 FDA
Pipeline program

silevertinib in combination with temozolomide

BDTX-1535-201

Phase 2 small_molecule active

Quick answer

silevertinib in combination with temozolomide for Glioblastoma (GBM) is a Phase 2 program (small_molecule) at Black Diamond Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Black Diamond Therapeutics
Indication
Glioblastoma (GBM)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials